Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0145-2126(94)00118-TPMID 7837820
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The macrocyclic lactone protein kinase C activator, bryostatin 1, either alone, or in conjunction with recombinant murine granulocyte-macrophage colony-stimulating factor, protects Balb/c and C3H/HeN mice from the lethal in vivo effects of ionizing radiation.

  1994cited by this paper
• Protein kinase C-mediated serine phosphorylation directly activates Raf-1 in murine hematopoietic cells.

  1994cited by this paper
• The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.

  1994cited by this paper
• Activation of beta-isozyme of protein kinase C (PKC beta) is necessary and sufficient for phorbol ester-induced differentiation of HL-60 promyelocytes. Studies with PKC beta-defective PET mutant.

  1994cited by this paper
• Activation of Raf-1 and mitogen-activated protein kinases during monocytic differentiation of human myeloid leukemia cells.

  1994cited by this paper
• Phorbol ester-induced myeloid differentiation is mediated by protein kinase C-alpha and -delta and not by protein kinase C-beta II, -epsilon, -zeta, and -eta.

  1993cited by this paper
• Differential modulation of protein kinase C isoforms in erythroleukemia during induced differentiation.

  1993cited by this paper
• In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.

  1993cited by this paper
• A phase I study of intravenous bryostatin 1 in patients with advanced cancer.

  1993cited by this paper
• Protein kinase C activators can interact synergistically with granulocyte colony-stimulating factor or interleukin-6 to stimulate colony formation from enriched granulocyte-macrophage colony-forming cells.

  1993cited by this paper
• Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor α Induction In Vivo

  1993cited by this paper
• Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.

  1993cited by this paper
• Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C.

  1993cited by this paper
• Differentiation and growth modulation of myeloid leukemia cells by the protein kinase C activating agent bryostatin-1.

  1993cited by this paper
• Protein kinase C activators can interact synergistically with granulocyte colony-stimulating factor or interleukin-6 to stimulate colony formation from enriched granulocyte-macrophage colony-forming cells

  1993cited by this paper
• Binding of [3H]bryostatin 4 to protein kinase C.

  1992cited by this paper
• The expression and possible roles of protein kinase C in haematopoietic cells.

  1992cited by this paper
• Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells.

  1992cited by this paper
• Bryostatin 1 modulates the proliferation and lineage commitment of human myeloid progenitor cells exposed to recombinant interleukin-3 and recombinant granulocyte-macrophage colony-stimulating factor.

  1992cited by this paper
• Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.

  1991cited by this paper
• Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte‐macrophage progenitors to recombinant GM‐CSF

  1991cited by this paper
• Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells.

  1990cited by this paper
• The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors.

  1990cited by this paper
• In vivo stimulation of murine haematopoiesis by the antineoplastic agent bryostatin-1.

  1990cited by this paper
• Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro.

  1990cited by this paper
• Varied differentiation responses of human leukemias to bryostatin 1.

  1989cited by this paper
• Putative involvement of protein kinase C in proliferation of human myeloid progenitor cells.

  1989cited by this paper
• Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins.

  1988cited by this paper
• Differing modulation of protein kinase C by bryostatin 1 and phorbol esters in JB6 mouse epidermal cells.

  1988cited by this paper
• Activation of human T lymphocytes by bryostatin.

  1988cited by this paper
• Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells.

  1988cited by this paper
• Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells.

  1987cited by this paper
• Isolation and structure of bryostatins 5–7

  1985cited by this paper
• Antineoplastic Components of Marine Animals

  1970cited by this paper

• The Phylum Bryozoa as a Promising Source of Anticancer Drugs

  2019cites this paper
• The Understudied Phylum Bryozoa as a Promising Source of Anticancer Drugs

  2019cites this paper
• Bryostatin 5 induces apoptosis in acute monocytic leukemia cells by activating PUMA and caspases.

  2013cites this paper
• The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.

  2012cites this paper
• Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

  2003cites this paper
• CHAPTER 12 – BIOSYNTHETIC PRODUCTS FOR ANTICANCER DRUG DESIGN AND TREATMENT: THE BRYOSTATINS

  2002cites this paper
• Chronic myeloid leukemia from basics to bedside

  1999cites this paper
• Effects of bryostatin-1 on chronic myeloid leukaemia-derived haematopoietic progenitors

  1999cites this paper
• Role of TNFα in bryostatin-induced inhibition of human hematopoiesis

  1999cites this paper
• Role of TNF alpha in bryostatin-induced inhibition of human hematopoiesis.

  1999cites this paper
• Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML.

  1998cites this paper
• Heterogenous effects of bryostatin on human myeloid leukemia clonogenicity: dose and time scheduling dependency.

  1996cites this paper
• Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency.

  1995cites this paper